Gaya Pharma, Africa’s leading full-service
Contract Research Organization (CRO), proudly announces the official launch of
its new subsidiary Gaya Pharma CI, based in Abidjan. This strategic milestone
marks a decisive step in our mission to advance clinical research, drive
real-world evidence (RWE) generation, and expand patient access to innovative
therapies across West Africa.
Côte d’Ivoire: A Strategic Hub for West Africa
Côte d’Ivoire has positioned itself as one
of the most dynamic healthcare and research ecosystems in the region. By
establishing Gaya Pharma CI, we are strengthening our footprint in West Africa
to better serve patients, institutions, and pharmaceutical partners in Côte
d’Ivoire, Senegal, Mali, Ghana, and beyond.
Our subsidiary is designed to become a
regional center of excellence for clinical trials, observational studies, and
health innovation programs. This expansion enables us to:
• Strengthen clinical research capacity in West Africa.
• Implement digital e-registries to collect robust, high-quality patient data.
• Conduct real-world evidence (RWE) studies tailored to local health systems
and populations.
• Improve access to innovation therapies through Patient Support Programs
(PSPs) and Patient Access Programs (PAPs).
• Support ministries of health and local institutions in developing
evidence-based healthcare policies.
Advanced Digital Tools: e-Registries and Beyond
At Gaya Pharma, we believe that technology
is the backbone of reliable healthcare research. With Gaya Pharma CI, we are
deploying advanced e-registries and electronic case report forms (e-CRF) that
allow:
• Accurate, real-time data collection and monitoring.
• Integration with hospital systems for seamless patient follow-up.
• Transparency and compliance with international standards.
• Reliable insights for public health decision-making.
These digital solutions, adapted to African
infrastructures, will accelerate evidence generation and empower local
healthcare professionals with actionable data.
Driving Real-World Evidence (RWE) Studies in Africa
One of the key missions of Gaya Pharma CI
is to lead the development of RWE studies in West Africa. By capturing data
from routine clinical practice and patient registries, we aim to:
• Evaluate treatment outcomes in real-world African settings.
• Measure the effectiveness and safety of innovative therapies.
• Support payers and regulators in health technology assessments.
• Provide pharmaceutical partners with evidence to guide market access
strategies.
RWE studies will not only advance science
but also bridge the gap between innovation and accessibility, ensuring that therapies
are adapted to the realities of African healthcare systems.
By Africans, For Africa
Our identity as an African CRO is central
to our vision. With our headquarters in Morocco and now Gaya Pharma CI in
Abidjan, we remain committed to solutions that reflect local contexts, cultural
diversity, and regulatory environments.
This expansion embodies our commitment to:
• Building sustainable local expertise in clinical research.
• Training healthcare professionals across West Africa.
• Supporting governments and institutions with data-driven healthcare
strategies.
• Positioning Africa as a global leader in research and innovation.
Looking Ahead
The launch of Gaya Pharma CI is more than
an expansion—it is a long-term investment in Africa’s health future. By combining
clinical research excellence, advanced digital solutions, and patient-focused
programs, we are paving the way for:
• Stronger research ecosystems.
• Greater patient access to innovative therapies.
• Data-driven healthcare policies that improve lives.
With Gaya Pharma CI, we reaffirm our
mission: to serve Africa with science, innovation, and compassion.